...Stefano Molica; Marco Rossi; David Allsup In addition to the European Society for Medical Oncology (ESMO) and National Comprehensive Cancer Network (NCCN) guidelines that are reference standards for the treatment of chronic lymphocytic leukemia (CLL) in Europe and the USA, several consensus...

...Ernesto Gargiulo; Rebecca Svanberg Teglgaard; Tereza Faitová; Carsten Utoft Niemann Background: Chronic lymphocytic leukemia (CLL) is a hematological malignancy characterized by immune dysfunction, which significantly contributes to increased morbidity and mortality due to infections. Summary...

...Tamar Tadmor; Guy Melamed; Hillel Alapi; Sivan Gazit; Tal Patalon; Lior Rokach Pregnancies following diagnosis of chronic lymphocytic leukemia (CLL) are rare events, mainly because the disease is typically diagnosed in the elderly. Literature on the topic is based only on case reports, and limited...

... role in the development of chronic lymphocytic leukemia. Nurse-like cells (NLCs) are one of the important elements of the microenvironment of CLL cells. The key role in the interactions of leukemic cells with NLCs is played by chemokines, which may interfere with the programmed cell death process...

...Shenmiao Yang; Rong Zhu; Nan Li; Yu Feng; Rui Zuo; Robert Peter Gale; Xiaojun Huang Introduction: Therapy of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with drugs such as ibrutinib and rituximab is often associated with immune suppression, opportunistic infections...

... course of SARS-CoV-2. In patients with chronic lymphocytic leukemia (CLL), infections are a main contributor to morbidity and mortality driven by an impaired immune system. Treatment initiation is likely to induce immune modulation that further increases the risk for severe infections. This article aims...

...Sanford Kempin; Zhuoxin Sun; Neil E. Kay; Elisabeth M. Paietta; Joseph J. Mazza; Rhett P. Ketterling; Olga Frankfurt; David F. Claxton; Joel N. Saltzman; Gordan Srkalovic; Natalie S. Callander; Gerald Gross; Martin S. Tallman Patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL...

...Uri Rozovski; Michael J. Keating; Zeev Estrov The immunoglobulin heavy chain gene ( IgHV ) mutation status correlates with the clinical outcome of patients with chronic lymphocytic leukemia (CLL) treated with chemoimmunotherapy. Why the survival rate of patients with unmutated IgHV is worse than...

...Beverly W. Baron; Michael J. Thirman; Mihai C. Giurcanu; Joseph M. Baron We reported that PIM1 kinase is expressed in the lymphocytes of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Quercetin, a naturally occurring flavonoid, is a dietary supplement...

... T cell function and stimulates the regulatory T cell population. The objectives were to investigate whether examining PD-1 expression in peripheral T cells of patients with chronic lymphocytic leukemia (CLL) reflected the disease phase and Binet stage and to compare the results with those in healthy...

... activation of these cells. There is growing evidence that chronic lymphocytic leukemia (CLL) cells exploit the PD-1 ligand (PD-L1) to resist antitumor immune reactions and maintain their survival by shaping their own microenvironment. Methods: We used a quantitative RT-PCR method to analyze PD-L1 gene...

...Dimitrios Tzachanis; Ayad Hamdan; Erik J. Uhlmann; Robin M. Joyce This is the case of a 79-year-old man with chronic lymphocytic leukemia who presented with Guillain-Barré syndrome with features overlapping with the Miller Fisher syndrome and Bickerstaff brainstem encephalitis and positive...

... and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Autoimmunity Chronic lymphocytic leukemia Alemtuzumab (Campath-1H; Genzyme, Cambridge, Mass., USA) is a chimeric...

... rare and has a poor prognosis. We describe the cases of high-grade large B-cell diffuse NHL in a 56-year-old male with chronic lymphocytic leukemia and in a 71-year-old female with previously unknown low-grade NHL, both with initial appearance of neurological symptoms. This report extends...

...Mariana Serpa; Israel Bendit; Fernanda Seguro; Flavia Xavier; Marcela Cavalcante; Daniel Steinbaum; Luciana Nardinelli; Vera Lucia Aldred; Henrique Moura de Paula; Pedro Enrique Dorlhiac-Llacer While chronic lymphocytic leukemia (CLL) and chronic myeloid leukemia (CML) are common diseases...

... from the skeleton by a humoral mediator. The latter mechanism is referred to as humoral hypercalcemia of malignancy (HHM). Frequent mediators of HHM are parathyroid hormone-related peptides (PTHrP). We report a patient with chronic lymphocytic leukemia and hypercalcemia induced by PTHrP. In contrast...

...Monika Podhorecka; Piotr Klimek; Malgorzata Kowal; Sylwia Chocholska; Agnieszka Bojarska-Junak; Anna Dmoszynska Chronic lymphocytic leukemia (CLL) is a heterogeneous disease with variable clinical course and prognosis. Therefore, the role of prognostic factors is very important, especially...

... and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Chronic lymphocytic leukemia Small lymphocytic lymphoma Hepatocellular carcinoma Hepatitis C virus...

...Olga A. Tsopra; Panos G. Ziros; Eleni D. Lagadinou; Argiris Symeonidis; Alexandra Kouraklis-Symeonidis; Eleni Thanopoulou; Maria K. Angelopoulou; Theodoros P. Vassilakopoulos; Gerassimos A. Pangalis; Nicholas C. Zoumbos Background/Aims: Disease-related anemia in chronic lymphocytic leukemia (CLL...

...K. Bremer; T.M. Fliedner The labeling pattern of in vitro 3 H-cytidine labeled blood lymphocytes was studied after autotransfusion in 2 hematologically normal patients and in 6 patients with untreated chronic lymphocytic leukemia. An in vitro incubation time of 45 min results in a rapid loss...